The stock gained 9.8 per cent to Rs 347.70 on shareholders’ approval to raise Rs 500 crore through an equity issue. The stock has appreciated 16 per cent in the last three days, after the company extended its drug-discovery collaboration with Eli Lilly and Co by another five years.
The company had posted net profit of Rs 183.50 crore in the first half of the current financial year, against net loss of Rs 49.96 crore during the same period a year ago.